Amundi Intellia Therapeutics, Inc. Transaction History

Amundi

$253 Billion
Q2 2024

A detailed history of Amundi transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Amundi holds 40,274 shares of NTLA stock, worth $846,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,274

Previous 57,328 29.75%

Holding current value

$846,156

Previous $1.58 Million 42.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $341,421 - $464,209	-17,054 Reduced 29.75%	40,274 $901,000
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $19,532 - $26,895	820 Added 1.45%	57,328 $1.58 Million
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $219,232 - $306,130	-9,466 Reduced 14.35%	56,508 $1.72 Million
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $660,763 - $956,664	20,897 Added 46.36%	65,974 $2.09 Million
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $943,826 - $1.26 Million	27,294 Added 153.48%	45,077 $1.84 Million
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $28,205 - $37,962	847 Added 5.0%	17,783 $662,000
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $215,532 - $406,858	-6,490 Reduced 27.7%	16,936 $590,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $691,200 - $919,122	12,819 Added 120.85%	23,426 $1.43 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $181,672 - $359,711	4,720 Added 80.18%	10,607 $677,000
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $218,512 - $446,212	3,750 Added 175.48%	5,887 $388,000
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $29,321 - $40,262	291 Added 15.76%	2,137 $191,000
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $244,355 - $326,335	1,846 New	1,846 $248,000

Others Institutions Holding NTLA

# of Institutions

326

Shares Held

88.8M

Call Options Held

673K

Put Options Held

865K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.6B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account